OMADA A/S to Receive Strategic Investment from CVC Capital Partners’ Growth Fund and GRO Capital
Omada A/S (“Omada” or the “Company”), a global leader of Identity Governance and Administration (“IGA”) software and services, today announced that CVC Capital Partners’ Growth Fund (“CVC Growth Partners” or “CVC”) and GRO Capital (“GRO”) have agreed to become new majority shareholders and provide further capital into the Company to accelerate growth.
CVC Growth Partners and GRO will partner with Omada’s management team to further accelerate Omada’s product innovation, grow its partner network in North America and Europe, enhance sales and marketing efforts, as well as continue expanding its strong position in Europe and building greater depth in the North American market.
Omada is headquartered in Copenhagen, Denmark, with over 270 employees across offices in Europe and North America. The Company helps its customers globally to govern and control users’ access rights to enterprise systems and data, reduce risk of accidental or wrongful data access, and ensure compliance with regulation (such as GDPR) as well as industry-specific legislation.
Omada’s software platform, the Omada Identity Suite (“OIS”), is a best-in-class next generation IGA solution. OIS, together with the Company’s unique best practice process framework for identity management and access governance, enables enterprises to manage identities and govern their access on an ongoing basis across heterogeneous IT systems, including major IT vendor platforms delivered on-premises and in the cloud, and a number of legacy and modern applications. The demand for Omada’s offerings has been increasing globally along with customer awareness of potential solutions to their complex identity governance challenges, and the Company has grown revenues at a compounded annual growth rate of over 40% for the last 2 years.
“We are excited about the partnership with CVC and GRO and we look forward to working with them to fulfil our joint vision to serve the majority of enterprises of the world with our strong Identity & Access Governance solution”, said Morten Boel Sigurdsson, CEO and founder of Omada. “CVC and GRO represent a unique combination of competencies that will support our expansion in North America, Europe and other markets. The need for IGA solutions is rapidly increasing across markets as more and more organizations realize the need for a flexible IGA solution to protect them from hacking, insider threats, increased compliance requirements and the consequences of GDPR.”
“The increasingly complex IT world and more stringent compliance requirements globally will continue to drive strong demand for Omada’s next generation identity governance solution, as the Company has proven its ability to successfully solve complex problems for its customers”, said Sebastian Kuenne, who leads CVC Growth Partners in Europe. “Omada represents an exciting opportunity and is a perfect fit for our growth fund, which focuses on high-growth software and technology-enabled business services companies. We, together with GRO, are thrilled to partner with Morten and the entire executive team to expand Omada’s offering and global presence."
“We have followed Omada for close to a decade and are very impressed with the product and their blue-chip customer base. This investment is perfectly aligned with GRO’s strategy of investing in outstanding technology companies and helping accelerate their growth”, said Morten Weicher, partner at GRO Capital. “Morten Sigurdsson has built a very strong team and assembled a deep bench of highly skilled and ambitious individuals operating in a unique culture of teamwork, delivery, and customer service.”
With the entrance of CVC and GRO, C5 Capital (“C5”) will no longer be shareholders in Omada. “We are pleased to have contributed to the growth of Omada since 2015”, said Andre Pienaar, managing partner and founder at C5 Capital.
Morten Weicher, Sebastian Kuenne, Lars Dybkjær (Managing Partner of GRO Capital), and John Clark (Managing Partner of CVC Growth Partners) will join Omada’s board of directors.
Closing of the transaction is anticipated to take place in December 2018, and is subject only to mandatory competition approvals.
About Omada A/S
Omada is a market-leading provider of IT security solutions and services for identity management and access governance. The company's innovative product portfolio delivered as a service and on-premise offers customers an integrated set of core services including identity lifecycle management, compliance control, provisioning, and access risk management across hybrid environments and delivers out-of-the box standardized, configurable IGA capabilities based on industry best-practice processes. Omada provides its innovative identity management and access governance solutions and services to an extensive customer portfolio of large and midsize enterprises globally within banking, utilities, public sector, securities and insurance, healthcare, and other verticals. Omada has a global partner network across Europe, the US, Africa, and Asia. For further information about Omada please visit: www.omada.net.
About CVC Capital Partners
CVC Capital Partners is a leading private equity and investment advisory firm. Founded in 1981, CVC today has a network of 24 offices and over 490 employees throughout Europe, Asia and the U.S. To date, CVC has secured commitments of over US$110 billion from some of the world's leading institutional investors across its private equity and credit strategies. In total, CVC currently manages over US$50 billion of assets. Today, funds managed or advised by CVC are invested in c.70 companies worldwide, employing c.212,000 people in numerous countries. Together, these companies have combined annual sales of over US$74 billion. For further information about CVC please visit: www.cvc.com.
About CVC Growth Partners
In 2014, CVC formed a new team to target smaller growth-oriented companies through its dedicated CVC Growth Partners fund. The fund focuses on middle-market high-growth companies in the software and technology-enabled business services sectors. The fund primarily targets equity investments between $50 million and $200 million in North America and Europe.
About GRO Capital
GRO Capital is a North European private equity fund with an exclusive focus on mature B2B software and tech enabled companies with strong growth prospects. GRO Capital serves as active owners developing portfolio companies with a view to create long-term value. The partners behind GRO Capital have been investors in more than 20 technology and software related companies. Omada is the first investment in GRO Fund II, a recently raised fund with a strategy to accelerate Northern European software companies. GRO Fund II has in its first closing received capital commitments from institutional investors and multi-lateral organisations, including leading Nordic institutional investors such as Danica Pension, Sampension and Dansk Vækstkapital II. Further, through the European Investment Fund, GRO Fund II benefits from the financial backing of the European Union under the European Fund for Strategic Investments set up under the Investment Plan for Europe. In addition to Omada, GRO Capital has in GRO Fund I invested in Auditdata, Boyum IT Solutions, Tacton Systems, Targit, Trackunit, and Trifork, all successful software providers. For further information about GRO Capital please visit: www.grocapital.dk
About C5 Capital
C5 Capital Limited (C5) is a specialist venture capital firm, focused on Innovative Technologies in Cyber Security, Artificial Intelligence and Cloud Computing. Headquartered in London, C5 also has offices in Washington, Munich, Luxembourg and Bahrain. For more information, visit: www.c5capital.com
Anne Dorthe Gyldenkærne
VP Global Marketing
+45 2018 1881
CVC Advisers Limited
Global Head of Communications
+44 207 420 4240
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom